Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Asse...
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Col...
"The government cannot love you, and any politics that works on a different assumption is destined for no good .”― Jonah Goldberg Today, we take a look at a small cap concern that has posted a nice rally in recent trading sessions. That said, the shares remain in 'Busted IPO...
The following slide deck was published by Assembly Biosciences, Inc. in conjunction with this Read more ...
The following slide deck was published by Assembly Biosciences, Inc. in conjunction with this Read more ...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Investors eagerly awaiting updates from the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, simply referred to as the Liver Meeting, weren't disappointed when presentations began publishing online in mid-November. Some of the most intriguing drug candidates in the ph...
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutc...
Assembly Biosciences ( ASMB +7% ) is up out the gate in reaction to encouraging data on its first- and second-generation hepatitis B virus (HBV) core inhibitors. The results were presented at The Liver Meeting in Boston. More news on: Assembly Biosciences, Inc., Healthcare stocks...
Carbonite (NASDAQ: CARB ) +25% on being acquired for $1.42B. More news on: Carbonite, Inc., Qurate Retail, Inc., Assembly Biosciences, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...